Osiris Therapeutics, Inc. Common Stock
OSIR
OSIR was delisted on the 16th of April, 2019.
67 hedge funds and large institutions have $127M invested in Osiris Therapeutics, Inc. Common Stock in 2013 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 21 increasing their positions, 26 reducing their positions, and 5 closing their positions.
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
8% more capital invested
Capital invested by funds: $117M → $127M (+$9.35M)
5% more funds holding
Funds holding: 64 → 67 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
19% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 26
52% less call options, than puts
Call options by funds: $3.34M | Put options by funds: $6.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$15.6M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.35M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$736K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$511K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$431K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$5.14M |
| 2 |
Morgan Stanley
New York
|
-$1.24M |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$450K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$339K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$210K |
OSIR Hedge Fund Activity: Q4 2013 in Review
67 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in Osiris Therapeutics, Inc. Common Stock (OSIR) for Q4 2013, worth a combined $127M — up 8% from $117M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new OSIR positions and 5 closed out — a net gain of 3 holders — while 21 added to existing stakes and 26 trimmed.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $15.6M. The largest seller was Invesco, cutting an estimated $5.14M.
- 67 institutional investors held Osiris Therapeutics, Inc. Common Stock (OSIR) as of Q4 2013, up from 64 in Q3 2013.
- Funds reported $127M of Osiris Therapeutics, Inc. Common Stock stock for Q4 2013, up 8% quarter-over-quarter.
- 8 funds opened new Osiris Therapeutics, Inc. Common Stock positions in Q4 2013 and 5 closed out, a net change of +3 holders.
- The largest Osiris Therapeutics, Inc. Common Stock buyer in Q4 2013 was Consonance Capital Management, an estimated $15.6M added.
- The largest Osiris Therapeutics, Inc. Common Stock seller in Q4 2013 was Invesco, an estimated $5.14M sold.
Based on aggregated 13F filings for Q4 2013.